Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
NovaBiotics’ platform technologies leverage defense strategies of the innate immune system and provide first-in-class antibacterial and antifungal therapies with potent activity against drug-resistant infections.
Inmunotek brings a range of skills and specialties together to create vaccine-based approaches for the treatment of allergy, recurrent infections and other immune-related diseases.
ADAPT biomaterial scaffolds outperform all competitors, having achieved 9 years without calcification or degradation and delivering positive health benefits to patients around the world.
The product-development partnership Medicines for Malaria Venture has evolved over the past 18 years into an organization with a strong network of partners and a track record of achievements.
Digital solutions, artificial intelligence, drug delivery, progress in precision medicine and immune-oncology – As always NLSDays Super Sessions tackle the big questions
Karius has developed a novel commercial cell-free DNA blood test able to rapidly and accurately detect more than 1,000 pathogens from a standard blood draw.
With core competencies in small-molecule drug design and synthesis, Shionogi continues to achieve success in and expand its infectious disease portfolio of both antibacterials and antivirals, many of which are home-grown products.
The Liverpool School of Tropical Medicine’s Research Centre for Drugs and Diagnostics’ public–private partnerships and delivery of translational projects help vulnerable people in resource-poor countries.
The market for drugs and vaccines to combat infectious diseases is expanding overall, but with wide variation in sales among its segments. This article analyzes the products, trends and dealmaking underlying these changes.
YUMAB, a global provider of fully human monoclonal antibody discovery and development, has relocated its headquarters to Germany’s hotspot of infectious research and is advancing new opportunities for the expedited development of prophylactic and therapeutic antibodies and vaccines to fight infectious diseases.
Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.
Using its antibiotic renewable technology, Helperby Therapeutics is developing a new class of antibiotics with activity against multidrug-resistant bacteria, including strains with transferable resistance to carbapenems and colistin.
Anti-infective company VenatoRx Pharmaceuticals has developed injectable and orally bioavailable broad-spectrum antibiotics that could help curb the expansion of antimicrobial resistance. The company is now seeking clinical and commercial partnerships.
BioCubaFarma, the Cuban organization of Biotechnology and Pharmaceutical Industries, manages the country’s efforts toward manufacturing medicines, diagnostics and medical equipment and providing high quality life science services to improve people’s health. BioCubaFarma serves as a gateway for potential partners and investors interested in accessing the extensive biopharma resources Cuba has to offer.
C-Bridge Capital specializes in the growing Chinese health care market and is using its expertize to identify emerging industry leaders and bring global innovation into China.
Fibrosis-related diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis, have generated a wave of deal and funding activity over recent years. Here, we highlight a selection of these deals.
An intravenously administered oncolytic virus platform delivers combinations of therapeutic genes specifically to solid tumors to enable a potent anticancer immune response while minimizing systemic toxicity.
